###begin article-title 0
Toll-Like Receptor 4 Decoy, TOY, Attenuates Gram-Negative Bacterial Sepsis
###end article-title 0
###begin p 1
Conceived and designed the experiments: KJ HMK JOL SCK GYK. Performed the experiments: KJ JEL SIH. Analyzed the data: KJ. Contributed reagents/materials/analysis tools: JEL HZK BSP. Wrote the paper: KJ SCK GYK.
###end p 1
###begin p 2
###xml 337 338 337 338 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</underline>
###xml 337 338 337 338 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>T</underline></bold>
###xml 345 347 345 347 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oy</underline>
###xml 345 347 345 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>oy</underline></bold>
###xml 735 742 735 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 487 494 <span type="species:ncbi:71164">hagfish</span>
###xml 918 922 <span type="species:ncbi:10090">mice</span>
Lipopolysaccharide (LPS), the Gram-negative bacterial outer membrane glycolipid, induces sepsis through its interaction with myeloid differentiation protein-2 (MD-2) and Toll-like receptor 4 (TLR4). To block interaction between LPS/MD-2 complex and TLR4, we designed and generated soluble fusion proteins capable of binding MD-2, dubbed TLR4 decoy receptor (TOY) using 'the Hybrid leucine-rich repeats (LRR) technique'. TOY contains the MD-2 binding ectodomain of TLR4, the LRR motif of hagfish variable lymphocyte receptor (VLR), and the Fc domain of IgG1 to make it soluble, productive, and functional. TOY exhibited strong binding to MD-2, but not to the extracellular matrix (ECM), resulting in a favorable pharmacokinetic profile in vivo. TOY significantly extended the lifespan, when administered in either preventive or therapeutic manners, in both the LPS- and cecal ligation/puncture-induced sepsis models in mice. TOY markedly attenuated LPS-triggered NF-kappaB activation, secretion of proinflammatory cytokines, and thrombus formation in multiple organs. Taken together, the targeting strategy for sequestration of LPS/MD-2 complex using the decoy receptor TOY is effective in treating LPS- and bacteria-induced sepsis; furthermore, the strategy used in TOY development can be applied to the generation of other novel decoy receptor proteins.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 232 235 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Martin1">[1]</xref>
###xml 517 520 505 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Beutler1">[2]</xref>
###xml 521 525 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Visintin1">[12]</xref>
Sepsis caused by Gram-negative bacterial infection is a life-threatening disease characterized by profound inflammatory responses, multi-organ dysfunction with marked thrombus formation, and a high mortality rate (approximately60%) [1]. Lipopolysaccharide (LPS), the Gram-negative bacterial outer membrane glycolipid, induces sepsis through its interaction with LPS-binding protein (LBP) or CD14 prior to subsequent formation of a complex with myeloid differentiation protein-2 (MD-2) and Toll-like receptor 4 (TLR4) [2]-[12].
###end p 4
###begin p 5
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Medzhitov1">[13]</xref>
###xml 365 369 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim1">[14]</xref>
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Bella1">[15]</xref>
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim1">[14]</xref>
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Pugin1">[16]</xref>
###xml 622 626 622 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Visintin2">[17]</xref>
###xml 711 715 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim1">[14]</xref>
###xml 717 721 714 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Ohto1">[18]</xref>
###xml 884 887 877 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Cohen1">[7]</xref>
###xml 888 891 881 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kawai1">[9]</xref>
###xml 893 897 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Beutler2">[19]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human TLR4 contains a 608-residue extracellular domain, a single transmembrane domain, and a 187-residue intracellular domain [13]. Crystal structural analysis has shown that TLR4 adopts the characteristic horseshoe-like shape of the LRR superfamily, with N-terminal (amino acids 27-202), central (amino acids 203-348), and C-terminal (amino acids 349-582) domains [14], [15]. MD-2 binds to the concave surface of the N-terminal and central domains of TLR4 [14]. In addition to TLR4-bound MD-2, the MD-2 protein is also secreted into the extracellular milieu in a soluble form, which is present in circulating blood [16], [17]. MD-2 has a beta-cup fold structure that forms a hydrophobic pocket for LPS binding [14], [18]. Binding of the LPS/MD-2 complex to TLR4 causes TLR4 dimerization, and results in the activation of NF-kappaB leading to acute and severe inflammation and sepsis [7]-[9], [19].
###end p 5
###begin p 6
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Visintin2">[17]</xref>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Hyakushima1">[20]</xref>
###xml 620 627 620 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 764 768 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim1">[14]</xref>
###xml 1210 1214 1210 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim1">[14]</xref>
###xml 1216 1220 1216 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim2">[21]</xref>
###xml 1448 1452 1448 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim1">[14]</xref>
###xml 1551 1555 1551 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Rossignol1">[22]</xref>
In this regard, blocking TLR4 signaling activation using a decoy receptor could be an effective way to prevent LPS- or Gram-negative bacteria-induced sepsis if applied prior to or after challenge. Although two research groups have tried to generate the extracellular domain of TLR4 protein as a decoy receptor for MD-2 [17], [20], it proved difficult to generate a substantial amount of the protein because it is insoluble, its production rate is extremely low, and it is hard to purify due to its intrinsic biochemical properties. Therefore, the trial of blocking TLR4 using a decoy receptor in preventing sepsis under in vivo conditions has not been achieved until now. To overcome these problems, we recently developed a novel method, 'the Hybrid LRR Technique [14]', to generate a massive amount of soluble extracellular domains of TLR4 protein. Variable lymphocyte receptors (VLRs) are a new type of immune receptors in jawless fish. These receptors resemble the adaptive immune receptors in jawed vertebrates. VLRs and TLRs commonly contain the LRR domain in the extracellular fragment, which is composed of a signal sequence, an N-terminal cap (LRRNT), several LRR modules, and a C-terminal cap (LRRCT) [14], [21]. Therefore, stable TLR4-VLR hybrid proteins can be generated in large amounts without any loss of the intrinsic structural integrity of TLR4 by replacing some LRR modules and LRRCT of TLR4 with those of VLR, termed TV3 and TV8 [14]. The TV3 and TV8 proteins are able to complex with MD-2 and Eritoran (a synthetic LPS antagonist) [22]. By fusion of the Fc domain of IgG1 to TV3 and TV8, we were able to generate dimeric TLR4 decoy receptor TOY, which is effective in treating LPS- and bacteria-induced sepsis.
###end p 6
###begin title 7
Results and Discussion
###end title 7
###begin p 8
###xml 103 104 103 104 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</underline>
###xml 103 104 103 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>T</underline></bold>
###xml 111 113 111 113 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oy</underline>
###xml 111 113 111 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>oy</underline></bold>
###xml 149 158 149 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 149 158 149 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g001"><bold>Figure 1A</bold></xref>
###xml 218 219 218 219 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</underline>
###xml 218 219 218 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>T</underline></bold>
###xml 223 224 223 224 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</underline>
###xml 223 224 223 224 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>f</underline></bold>
###xml 235 236 235 236 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</underline>
###xml 235 236 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>e</underline></bold>
###xml 252 261 252 261 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 252 261 252 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g001"><bold>Figure 1A</bold></xref>
###xml 382 391 382 391 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 382 391 382 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g001"><bold>Figure 1B</bold></xref>
###xml 624 628 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Hwang1">[23]</xref>
###xml 836 845 776 785 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 836 845 776 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g001"><bold>Figure 1C</bold></xref>
###xml 982 991 922 931 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 982 991 922 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g001"><bold>Figure 1C</bold></xref>
###xml 994 1002 934 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 1119 1127 1059 1067 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1119 1127 1059 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g002"><bold>Figure 2</bold></xref>
###xml 1132 1141 1072 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007403.s001">Figure S1</xref>
###xml 1132 1141 1072 1081 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007403.s001">Figure S1</xref></bold>
###xml 1251 1252 1191 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1252 1253 1192 1193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sub>
###xml 1355 1364 1259 1268 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 1355 1364 1259 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g002"><bold>Figure 2C</bold></xref>
###xml 1457 1465 1361 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 1612 1628 1512 1528 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A and 3B</bold>
###xml 1612 1628 1512 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g003"><bold>Figure 3A and 3B</bold></xref>
###xml 1698 1707 1594 1603 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3C</bold>
###xml 1698 1707 1594 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g003"><bold>Figure 3C</bold></xref>
###xml 9 14 <span type="species:ncbi:9606">human</span>
We fused human IgG-Fc to the carboxy-terminal portion of TV3 and TV8, and named the resulting products TLR4 decoy receptor-3 and -8 (TOY3 and TOY8) (Figure 1A). As a control, we also produced a fusion of IgG-Fc to the TLR4 full-length ectodomain (TFE; Figure 1A). We used computer modeling based on crystal structures to illustrate the potential structures of the three constructs (Figure 1B). We were able to produce the TFE, TOY3, and TOY8 proteins in CHO cells at rates of 0.1, approximately20, and approximately15 mg/L. The production rates of TOY3 and TOY8 are currently amplified by the methotrexate selection process [23]. The purified TFE, TOY3, and TOY8 under reducing conditions revealed predominantly single bands of the expected molecular masses of approximately110, approximately65 and, approximately105 kDa, respectively (Figure 1C). Under non-reducing conditions, the recombinant proteins were present as disulfide-linked dimers due to the presence of the Fc domain (Figure 1C). In vitro binding analysis revealed that TFE, TOY3, or TOY8 could interact not only with MD-2 but also with LPS/MD-2 complex (Figure 2 and Figure S1). Surface plasmon resonance analyses revealed that all three proteins directly interacted with MD-2, and the KD of TFE, TOY3, and TOY8 binding to MD-2 was approximately81, approximately76, and approximately56 nM (Figure 2C). Thus, the VLR component in TOY did not substantially alter the binding affinity for MD-2. In vitro analyses demonstrated that both TOY3 and TOY8 largely inhibited LPS-induced NF-kappaB activation in primary cultured lymphatic endothelial cells (Figure 3A and 3B) and also diminished LPS-induced TNF-alpha secretion in macrophages (Figure 3C).
###end p 8
###begin title 9
Structures of TFE and TOY constructs.
###end title 9
###begin p 10
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 131 138 <span type="species:ncbi:71164">hagfish</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
(A) Schematic diagrams of the constructs showing the relative sizes of the human TLR4 ectodomain (TLR4), VLRB.61 fragment (VLR) of hagfish, and human IgG-Fc (Fc). Numbers indicate amino acids of the parental proteins. (B) Crystal structures based on computer modeling. The domains depicted are TLR4 (red), VLR (yellow), and Fc (blue). (C) Each 2 microg of reduced (R) and nonreduced (NR) proteins was separated by SDS-PAGE and stained with Coomassie blue. Molecular masses (kDa) are indicated at left.
###end p 10
###begin title 11
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro binding analysis reveals that LPS binds to TFE, TOY3, or TOY8 through MD-2 and BIAcore analysis of interaction between TFE, TOY3, or TOY8 and MD-2.
###end title 11
###begin p 12
###xml 324 325 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 369 370 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 380 381 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 387 393 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
(A) 200 ng of Fc, TFE, TOY3, or TOY8 were coated onto 96-well plates. FITC-labeled LPS (10 microg/ml) was incubated in the presence or absence of MD-2 (1 microg/ml) in each indicated well for 2 hr. The fluorescence signal was measured by IVIS imaging. (B) Fluorescence was quantified and expressed as radiance (photon/sec/cm2/steradian). Bars represent means +/- S.D. (n = 4). *, P<0.05 versus Fc+hMD-2+FITC-LPS (1). The x-axis numbering represents the number of each well in (A). (C) Sensorgrams for the association and dissociation of MD-2 on immobilized TFE, TOY3, or TOY8. One microgram of TFE, TOY3, or TOY8 was immobilized on a Sensor Chip CM5 (BIAcore) using N-hydroxysuccinimide (NHS) and 1-ethyl-3(3-dimethylaminopropyl) carbodiimide (EDC) amine coupling reagent at approximately 2,000 resonance units (RU). As a control, BSA protein was immobilized on another portion of the same chip. Recombinant MD-2 proteins were then applied onto the immobilized TFE, TOY3, or TOY8 surfaces, and the amount captured was recorded in sensorgrams as RU. All samples were in running buffer to minimize bulk effects. The kinetic parameters of the binding interactions were calculated from the sensorgrams by nonlinear curve fitting using BIAEVALUATION software (BIAcore). RU represents resonance units.
###end p 12
###begin title 13
Pre-incubation of TFE, TOY3, and TOY8 markedly attenuates LPS-induced NF-kappaB activation in primary cultured lymphatic endothelial cells and TNF-alpha secretion in peritoneal macrophages.
###end title 13
###begin p 14
###xml 925 926 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 936 937 918 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1236 1237 1208 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1247 1248 1219 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 992 997 <span type="species:ncbi:10090">mouse</span>
LEC (primary lymphatic microvascular endothelial cells derived from human adult dermis) were purchased from Cambrex Inc. (East Rutherford, NJ) and maintained in endothelial cell basal medium-2 with growth supplements (EBM-2 MV). Passage 4-6 LEC were incubated in EBM-2 MV containing 1 % FBS for 8 hr and then with 1 microg/ml of Fc, TFE, TOY3, or TOY8 for 15 min, and then the LEC were treated with LPS (500 ng/ml) for 30 min. (A) For determination of NF-kappaB activation, nuclear translocalization of p65 (a subunit of NF-kappaB) was analyzed by immunostaining (green). Nuclei were counterstained with DAPI (blue). Arrows indicate nuclear translocalization of p65. Scale bars, 100 microm. (B) Cells positive for p65 intranuclear staining (white arrows) were counted among 100 cells arbitrarily chosen in 4 different regions, and the values presented as a percentage of the total cell number. Bars represent means +/- S.D. (n = 4). *, P<0.05 versus Fc. (C) Primary cultured macrophages from mouse peritoneal cavity were pre-treated with 1.0 microg/ml of Fc, TOY3, or TOY8 for 30 min, and then were treated with LPS (100 ng/ml) for 4 hr. Culture media were sampled, and levels of TNF-alpha were measured. Bars represent means +/- S.D. (n = 5). *, P<0.05 versus Fc.
###end p 14
###begin p 15
###xml 101 108 101 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 445 453 445 453 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 445 453 445 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g004"><bold>Figure 4</bold></xref>
###xml 600 609 600 609 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 600 609 600 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g005"><bold>Figure 5A</bold></xref>
###xml 627 634 627 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 998 1001 986 989 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1/2</sub>
###xml 1029 1038 1005 1014 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B</bold>
###xml 1029 1038 1005 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g005"><bold>Figure 5B</bold></xref>
###xml 1050 1051 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1092 1093 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1093 1096 1069 1072 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 1207 1208 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1208 1211 1176 1179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 1278 1279 1238 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1279 1282 1239 1242 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 1408 1416 1360 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1532 1539 1484 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1610 1617 1562 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
###xml 1044 1048 <span type="species:ncbi:10090">mice</span>
The isoelectric point (pI) of a recombinant protein affects its bioavailability and pharmacokinetics in vivo. High-pI proteins suffer from poor bioavailability because they adhere nonspecifically to the negatively charged proteoglycans of the extracellular matrix (ECM). While the theoretical pI values of TFE, TOY3, and TOY8 are 5.7, 11.8, and 6.0, their actual pI values are 5.0, 5.2, and 5.5, possibly due to abundant N-linked glycosylation (Figure 4). Indeed, the ECM binding assay demonstrated that TFE, TOY3, and TOY8 had minimal binding to ECM, whereas Flt1-Fc (pI 9.1) bound strongly to ECM (Figure 5A). To examine the in vivo pharmacokinetic profiles of the proteins, we performed a single intraperitoneal injection (5 mg/kg) of TOY3, TOY8, or Flt1-Fc recombinant protein into mice. TOY3 and TOY8 proteins were rapidly absorbed from the peritoneal cavity into systemic circulation. The proteins reached maximum levels in blood at 1approximately2 hr after injection, and their half-lives (t1/2) were approximately2 days (Figure 5B). In mice (n = 4), TOY3 had a maximal concentration (Cmax) of 7.00+/-0.13 microg/ml and AUC (total "area under the curve of concentration") of 20.50+/-0.96, TOY8 had a Cmax of 7.03+/-0.85 microg/ml and AUC of 18.27+/-1.24, and Flt1-Fc had Cmax of 5.28+/-0.49 microg/ml and AUC of 9.96+/-0.84. Thus, the pharmacokinetic profiles of the proteins were correlated to their in vitro ECM adhesion properties. TOY3 and TOY8 have relatively high bioavailability and excellent pharmacokinetic profiles in vivo, raising the possibility that TOY could block LPS/MD-2/TLR4 signaling in vivo by providing a decoy for TLR4.
###end p 15
###begin title 16
Isoelectric focusing and glycosylation analysis of TFE, TOY3, and TOY8.
###end title 16
###begin p 17
(A) 20 microg of the indicated protein was loaded on an IsoGel Agarose IEF Plate and run at 50 mA constant current for 3 hr. The gels were stained with Coomassie blue. Each bracket marks the pI range of the indicated protein. Reference pI values are indicated by the standard marker proteins (SMP). (B) 2 microg of the indicated protein was digested with O-glycosidase (O) and PNGase F (N) and was separated by SDS-PAGE and stained with Coomassie blue. Each undigested protein was used as control (U). Molecular masses (kDa) are indicated at left.
###end p 17
###begin title 18
###xml 47 55 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
TOY3 and TOY8 have low binding affinity to ECM in vitro and display excellent pharmacokinetic profiles in vivo.
###end title 18
###begin p 19
###xml 172 173 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 183 184 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 190 196 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 499 500 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 510 511 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 517 523 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
(A) ELISA analysis depicting the binding affinity for different concentrations (0.3, 1, 3, 10, 30 nM) of each indicated protein to ECM. Values are given as means +/- S.D. (n = 4). *, P<0.05 versus Fc. (B) Pharmacokinetic profiles. The indicated protein (5 mg/kg) was injected intraperitoneally into C57BL/6 mice. Then blood samples were taken from the tail vein at 1, 2, 4, 8, 12, 24, 48, 96, and 144 hrs, and serum levels of the proteins were measured by ELISA. Values are given as means +/- S.D. (n = 4). *, P<0.05 versus Fc.
###end p 19
###begin p 20
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 444 445 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 523 524 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 558 574 510 526 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A and 6B</bold>
###xml 558 574 510 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g006"><bold>Figure 6A and 6B</bold></xref>
###xml 956 957 884 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1035 1036 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1070 1086 974 990 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6C and 6D</bold>
###xml 1070 1086 974 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g006"><bold>Figure 6C and 6D</bold></xref>
###xml 1534 1535 1414 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1610 1619 1490 1499 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6E</bold>
###xml 1610 1619 1490 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g006"><bold>Figure 6E</bold></xref>
###xml 1903 1904 1783 1784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1913 1922 1793 1802 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6F</bold>
###xml 1913 1922 1793 1802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g006"><bold>Figure 6F</bold></xref>
###xml 2144 2145 2000 2001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2244 2245 2076 2077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2678 2679 2486 2487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2765 2766 2549 2550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2807 2823 2591 2607 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7A and 7B</bold>
###xml 2807 2823 2591 2607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g007"><bold>Figure 7A and 7B</bold></xref>
###xml 3041 3042 2801 2802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 3127 3128 2863 2864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 656 660 <span type="species:ncbi:10090">mice</span>
###xml 837 841 <span type="species:ncbi:10090">mice</span>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
###xml 1283 1287 <span type="species:ncbi:10090">mice</span>
###xml 1407 1411 <span type="species:ncbi:10090">mice</span>
###xml 1468 1472 <span type="species:ncbi:10090">mice</span>
###xml 1572 1576 <span type="species:ncbi:10090">mice</span>
###xml 1682 1686 <span type="species:ncbi:10090">mice</span>
###xml 2355 2359 <span type="species:ncbi:10090">mice</span>
To explore whether the TOY proteins could ameliorate sepsis in vivo, eight experiments were performed. For the first and second experiment, 20 mg/kg of TOY3 or TOY8 was given to mice at 30 min prior to or at 1 hr after administration of LPS (15 mg/kg) ('preventive model' or 'therapeutic model'). Both TOY3- and TOY8-treated mice had an extended lifespan compared to Fc-treated mice (50% survival: approximately58 hr versus approximately22 hr, P<0.001 in the preventive model; approximately49 hr versus approximately22 hr, P<0.001 in the therapeutic model) (Figure 6A and 6B). For the third and fourth experiment, 20 mg/kg of TOY3 or TOY8 was given to the mice at 1 hr prior to or at 1 hr after generation of acute peritonitis by cecal ligation and puncture (CLP) ('preventive model' or 'therapeutic model'). Both TOY3- and TOY8-treated mice had a prolonged lifespan compared to Fc-treated mice (50% survival: approximately74 hr versus approximately29 hr, P<0.001 in the preventive model; approximately60 hr versus approximately32 hr, P<0.001 in the therapeutic model) (Figure 6C and 6D). Thus, surprisingly, both TOY3 and TOY8 showed prominent preventive and therapeutic effects in the LPS- and CLP-induced sepsis models. For the fifth experiment, 20 mg/kg of TOY3 was given to the mice at 1 hr and 12 hr after administration of LPS (15 mg/kg) ('repeated treatment to therapeutic model'). The TOY3-treated mice had a markedly extended lifespan compared to Fc-treated mice (50% survival: approximately60 hr versus approximately26 hr, P<0.001), and the 40% of TOY3-treated mice were completely rescued to live (Figure 6E). For the sixth experiment, 20 mg/kg of TOY3 was given to the mice at 1 hr and 12 hr after generation of CLP ('repeated treatment to therapeutic model'). The repeated administration of TOY3 led to a dramatic increase in survival up to 96 hr after CLP (TOY3 versus Fc; 60% versus 0%, P<0.001) (Figure 6F). Thus, the repeated treatments with TOY3 markedly attenuated lethality in both the LPS- and CLP-induced sepsis models compared to the single treatment of TOY3 (50% survival: approximately60 hr versus approximately50 hr, P<0.01 in the LPS-induced sepsis model; 70% survival: approximately60 hr versus approximately50 hr, P<0.01 in the CLP-induced sepsis model). For the seventh and eighth experiments, 20 mg/kg of TOY3 was given to mice at 6 hr and 12 hr after administration of LPS (15 mg/kg) or the CLP procedure ('clinically relevant model'). These repeated administrations of TOY3 also significantly improved survival compared to the controls in both the LPS- and CLP-induced sepsis models (50% survival: approximately69 hr versus approximately21 hr, P<0.001 in the LPS-induced sepsis model; approximately84 hr versus approximately32 hr, P<0.001 in the CLP-induced sepsis model) (Figure 7A and 7B). These repeated treatments with TOY3 markedly attenuated lethality in both the LPS- and CLP-induced sepsis models compared to the single treatment of TOY3 (50% survival: approximately70 hr versus approximately50 hr, P<0.01 in the LPS-induced sepsis model; approximately84 hr versus approximately60 hr, P<0.01 in the CLP-induced sepsis model). Therefore, repeated treatments with TOY3 could ameliorate sepsis even in a more clinically relevant situation.
###end p 20
###begin title 21
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
TOY attenuates lethality in two sepsis mouse models and is effective in both prophylactic and therapeutic treatments.
###end title 21
###begin p 22
###xml 491 492 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
(A-D) 20 mg/kg of Fc, TOY3, or TOY8 was given intraperitoneally to mice 30 min before (A) or 1 hr after (B) intraperitoneal administration of LPS (15 mg/kg). The protein is given 1 hr before (C) or 1 hr after (D) generation of CLP. (E and F) 20 mg/kg of Fc or TOY3 was given intraperitoneally to the mice at 1 hr and 12 hr after intraperitoneal administration of LPS (15 mg/kg) (E) or at 1 hr and 12 hr after generation of CLP (F). % Survival represents remaining live mice from total mice (n = 10-11).
###end p 22
###begin title 23
TOY ameliorates sepsis in clinically relevant models.
###end title 23
###begin p 24
###xml 231 232 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
(A and B) 20 mg/kg of Fc or TOY3 was given intraperitoneally to mice at 6 hr and 12 hr after intraperitoneal administration of LPS (15 mg/kg) (A) or generation of CLP (B). % Survival represents remaining live mice from total mice (n = 5).
###end p 24
###begin p 25
###xml 203 206 199 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Beutler1">[2]</xref>
###xml 208 212 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Riedemann1">[24]</xref>
###xml 416 418 408 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF</italic>
###xml 423 431 411 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B-RE-luc</italic>
###xml 431 435 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Carlsen1">[25]</xref>
###xml 602 604 590 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF</italic>
###xml 609 617 593 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B-RE-luc</italic>
###xml 678 680 662 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF</italic>
###xml 685 693 665 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B-RE-luc</italic>
###xml 700 716 680 696 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8A and 8B</bold>
###xml 700 716 680 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g008"><bold>Figure 8A and 8B</bold></xref>
###xml 814 816 794 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF</italic>
###xml 821 829 797 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B-RE-luc</italic>
###xml 836 852 812 828 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8A and 8B</bold>
###xml 836 852 812 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g008"><bold>Figure 8A and 8B</bold></xref>
###xml 1081 1097 1050 1066 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C and 8D</bold>
###xml 1081 1097 1050 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g008"><bold>Figure 8C and 8D</bold></xref>
###xml 1214 1223 1176 1185 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C</bold>
###xml 1214 1223 1176 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g007"><bold>Figure 8C</bold></xref>
###xml 1266 1275 1228 1237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8D</bold>
###xml 1266 1275 1228 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007403-g008"><bold>Figure 8D</bold></xref>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 694 698 <span type="species:ncbi:10090">mice</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 1075 1079 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
Gram-negative bacterial sepsis is characterized by increased secretions of proinflammatory cytokines and thrombus formation in blood vessels, and both effects are brought through activation of NF-kappaB [2], [24]. To determine whether TOY attenuates NF-kappaB activation and subsequent secretion of proinflammatory cytokines and thrombus formation, we monitored these parameters in the LPS 'therapeutic model' using NFkappaB-RE-luc[25] and wild-type mice. At 24 hr after LPS (1 mg/kg) administration, the luminescence signal examined by IVIS imaging system was markedly up-regulated in most regions of NFkappaB-RE-luc mice, whereas the signal was barely detected in PBS-treated NFkappaB-RE-luc mice (Figure 8A and 8B). Both TOY3 and TOY8 significantly attenuated the LPS-induced up-regulation of the signal in the NFkappaB-RE-luc mice (Figure 8A and 8B). At 6 or 24 hr after LPS (7.5 mg/kg) administration, levels of TNF-alpha, IL-1beta, and IL-6 in plasma and thrombi in the blood vessels of liver, adrenal cortex, lung, and brain were profoundly increased in the wild-type mice (Figure 8C and 8D). The mice treated with either TOY3 or TOY8 had markedly reduced levels of TNF-alpha, IL-1beta, and IL-6 in plasma (Figure 8C), and fewer thrombi in the blood vessels (Figure 8D). Thus, TOY attenuated LPS-induced NF-kappaB activation, which increases the secretion of proinflammatory cytokines and results in thrombus formation in multiple organs.
###end p 25
###begin title 26
TOY attenuates LPS-induced NF-kappaB activation, secretion of proinflammatory cytokines, and thrombus formation.
###end title 26
###begin p 27
###xml 10 12 10 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF</italic>
###xml 17 25 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B-RE-luc</italic>
###xml 363 364 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 412 413 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 425 426 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 432 438 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 444 445 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 447 448 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 454 460 448 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 760 761 745 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 773 774 758 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 780 786 765 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 498 502 <span type="species:ncbi:10090">mice</span>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
(A and B) NFkappaB-RE-luc mice were injected intraperitoneally with control PBS (C) or 20 mg/kg of Fc, TOY3 (T3), or TOY8 (T8) at 1 hr after intraperitoneal administration of C or LPS (1 mg/kg). At 24 hr later, the luminescence signals from the whole body were examined by IVIS imaging (A). The luminescence was quantified and expressed as radiance (photon/sec/cm2/steradian) (B). Bars represent means +/- S.D. (n = 3-4). *, P<0.05 versus C+C; #, P<0.05 versus C+LPS or Fc+LPS. (C and D) Wild-type mice were injected intraperitoneally with C or 20 mg/kg of Fc, T3, or T8 at 1 hr after intraperitoneal administration of LPS (7.5 mg/kg) or C. At 6 and 24 hr later, plasma levels of TNF-alpha, IL-1beta, and IL-6 were measured (C). Bars represent means +/- S.D. (n = 4-5). *, P<0.05 versus Fc+LPS. At 24 hr after treatment, the mice were anesthetized, and samples of liver, adrenal gland, lung, and brain were H&E stained (D). Arrows indicate thrombi in the blood vessels. Scale bars, 100 microm.
###end p 27
###begin p 28
###xml 695 702 695 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kim1">[14]</xref>
###xml 1256 1260 1256 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Roger1">[26]</xref>
###xml 1415 1419 1415 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Roger1">[26]</xref>
###xml 1421 1425 1421 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Daubeuf1">[27]</xref>
###xml 1505 1509 1505 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Rossignol1">[22]</xref>
###xml 1511 1515 1511 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Fort1">[28]</xref>
###xml 1790 1793 1790 1793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Barton1">[8]</xref>
###xml 1795 1798 1795 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kawai1">[9]</xref>
###xml 1891 1895 1891 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Wu1">[29]</xref>
###xml 1904 1908 1904 1908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Tasaka1">[30]</xref>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 2114 2122 <span type="species:ncbi:9606">patients</span>
In this study, we report for the first time the production of a TLR4 decoy receptor, TOY, which can be easily generated in large amounts. We also show for the first time that a modified decoy receptor of TLR4, TOY, is effective not only for prevention, but also for treatment of LPS- and bacteria-induced sepsis in mice. Because TOY would be used only once or twice during treatment of a life-threatening septic condition, the immune reaction against to TOY is not being considered. TOY3 and TOY8 produced almost identical effects in preventing sepsis; since TOY3 bears only the 'A patch' of the TLR4, this result implies that the 'A patch' of the TLR4 ectodomain is sufficient for MD-2 binding in vivo[14]. These findings give us additional structural information in TLR4 biology which shows that further application of TLR4 can be achieved with only the MD-2 minimal binding portion. Considering that TOY3 has a slightly higher production rate and smaller molecular size, it will be the most favorable construct for therapeutic use of TOY in the future. Recently, Roger et al. reported that a blocking antibody against the N-terminal and central domains of TLR4 also produced preventive and therapeutic effects in LPS- and bacteria-induced sepsis models [26]. Thus, targeting TLR4 either by the blocking antibody or decoy receptor such as TOY could be an amenable tool to relieve LPS- and bacteria-induced sepsis [26], [27]. In comparison, several lipid A analogs that are competitive inhibitors of LPS [22], [28] are able to target only LPS-free MD-2, but not LPS-bound MD-2, whereas TOY could sequester both free and bound forms of MD-2. Furthermore, since LBP and CD14 play accessory roles in LPS recognition by TLR4/MD-2 while MD-2 binds to LPS directly and induces TLR4 dimerization [8], [9], the efficacy of targeting TLR4/MD-2 using TOY could be different from that of blocking LBP [29] or CD14 [30]. Therefore, the effectiveness of TOY and blockers of LBP or CD14 should be carefully compared in future studies. Taken together, TOY would be an effective alternative therapeutic molecule for treatment of patients with bacterial sepsis, and our method provides a new platform biotechnology to generate novel decoy receptor from TLR proteins.
###end p 28
###begin title 29
Materials and Methods
###end title 29
###begin title 30
Generation of recombinant proteins
###end title 30
###begin p 31
###xml 434 438 434 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Hwang1">[23]</xref>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dhfr</italic>
###xml 583 587 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dhfr</italic>
###xml 675 679 675 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dhfr</italic>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 201 208 <span type="species:ncbi:71164">hagfish</span>
###xml 246 251 <span type="species:ncbi:9606">human</span>
###xml 312 327 <span type="species:ncbi:10029">Chinese hamster</span>
###xml 996 1002 <span type="species:ncbi:9913">bovine</span>
Gene constructs encoding different sizes of the ectodomain of human TLR4 [TFE (amino acid residues 27-631), TOY3 (amino acid residues 27-227), and TOY8 (amino acid residues 27-527)], the LRR module of hagfish VLR-B.61 (VLR), and the Fc domain of human IgG (Fc) were cloned into the pCMV-dhfr vector. Recombinant Chinese hamster ovary (rCHO) cells expressing TFE, TOY3, or TOY8 were established following a previously described method [23]. Briefly, the cells were established by transfection of a vector containing the dihydrofolate reductase (dhfr) and TFE, TOY3, or TOY8 gene into dhfr-deficient CHO cells (CRL-9096, American Type Culture Collection). This was followed by dhfr/methotrexate (MTX)-mediated gene amplification. Stable rCHO cells secreting the highest amount of TFE, TOY3, or TOY8 were selected with serially-increasing concentrations of MTX (0.001-0.08 microM, Sigma-Aldrich). Then the cells were grown and maintained in HyQ SFM4CHO (Hyclone) supplemented with 1% dialyzed fetal bovine serum (Invitrogen) and 0.08 microM MTX. After 4 days, the culture media containing recombinant proteins were harvested, and the recombinant TFE, TOY3, or TOY8 proteins were purified by using Protein-A sepharose affinity chromatography with subsequent acid elution and neutralization. After purification, each protein was quantitated using the Bradford assay and confirmed with Coomassie blue staining of an SDS-PAGE gel.
###end p 31
###begin title 32
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro binding assay
###end title 32
###begin p 33
200 ng of BSA or MD-2 was coated onto 96-well plates. After blocking with 1% BSA for 1 hr, 40 microg/ml of Fc, TFE, TOY3, or TOY8 was incubated in each well for another 1 hr with or without FITC-labeled LPS (10 microg/ml). An HRP-conjugated anti-Fc antibody was incubated in each well for 1 hr, and then HRP substrate was added to each well. The fluorescence signal was measured by IVIS imaging, and the absorbance was measured by microplate reader (Bio-Rad).
###end p 33
###begin title 34
Surface plasmon resonance assay and isoelectric focusing
###end title 34
###begin p 35
Binding between TFE, TOY3, or TOY8 and MD-2 were analyzed with the BIAcore 3000 (BIAcore AB). One microgram of TFE, TOY3, or TOY8 was immobilized on a Sensor Chip CM5 (BIAcore) using N-hydroxysuccinimide (NHS) and 1-ethyl-3(3-dimethylaminopropyl) carbodiimide (EDC) amine coupling reagent at approximately 2,000 resonance units (RU). As a control, BSA protein was immobilized on another portion of the same chip. Recombinant MD-2 proteins were then applied onto the immobilized TFE, TOY3, or TOY8 surfaces, and the amount captured was recorded in sensorgrams as RU. All samples were in running buffer to minimize bulk effects. The kinetic parameters of the binding interactions were calculated from the sensorgrams by nonlinear curve fitting using BIAEVALUATION software (BIAcore). To measure isoelectric points, 20 microg of each protein sample and standard marker proteins were loaded on an IsoGel Agarose IEF Plate pH 3-10 strip (Cambrex) and run at 50 mA constant current for 3 hr using 1 M phosphoric acid at the anode and 1 M sodium hydroxide at the cathode. The gels were stained with Coomassie blue.
###end p 35
###begin title 36
Glycosylation analysis of recombinant proteins
###end title 36
###begin p 37
Two microg of TFE, TOY3, or TOY8 was incubated with O-glycosidase or PNGase F (QA-Bio) according to manufacturer's protocol, and then the protein was run on SDS-PAGE and the glycosylation pattern was analyzed by the migration shift after Coomassie blue staining.
###end p 37
###begin title 38
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro assays for NF-kappaB and TNF-alpha
###end title 38
###begin p 39
###xml 162 166 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Kang1">[31]</xref>
###xml 877 878 865 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 245 250 <span type="species:ncbi:9606">human</span>
###xml 634 639 <span type="species:ncbi:10090">mouse</span>
###xml 798 802 <span type="species:ncbi:10090">mice</span>
###xml 976 982 <span type="species:ncbi:9913">bovine</span>
NF-kappaB activity was assessed by immune-localization of p65 in nuclei of primary cultured lymphatic endothelial cells according to methods previously described [31]. Briefly, LEC (primary lymphatic microvascular endothelial cells derived from human adult dermis) were purchased from Cambrex Inc. (East Rutherford) and maintained in endothelial cell basal medium-2 with growth supplements (EBM-2 MV). Passage 4-6 LEC were incubated in EBM-2 MV containing 1 % FBS for 8 hr and then with 1 microg/ml of Fc, TFE, TOY3, or TOY8 for 15 min, and then the LEC were treated with LPS (500 ng/ml) for 30 min. Primary cultured macrophages from mouse peritoneal cavity were used to assay TNF-alpha secretion. Three days after intraperitoneal injection of 1 ml of 3% thioglycolate into 9-week-old male C57BL/6 mice, we harvested macrophages by peritoneal lavage with PBS. We incubated 1x106 macrophages per experimental condition in RPMI 1640 (Lonza) supplemented with 10% dialyzed fetal bovine serum (Invitrogen). The macrophages were pre-incubated for 30 min with 1 microg/ml of Fc, TOY3, or TOY8, and then treated with LPS (100 ng/ml) for 4 hr. Culture media were sampled, and levels of TNF-alpha were measured by ELISA (R&D systems).
###end p 39
###begin title 40
ECM binding assay and pharmacokinetic analysis
###end title 40
###begin p 41
###xml 195 199 <span type="species:ncbi:10090">mice</span>
ECM-coated 96-well plates (Becton Dickinson) were used for ECM binding assays. Each recombinant protein (100 microg of Fc, TOY3, or TOY8) was injected subcutaneously into 8-week-old male C57BL/6 mice (approximately25 g body weight), then the amount of each recombinant protein in blood was measured at the indicated times by sandwich ELISA.
###end p 41
###begin title 42
Animals
###end title 42
###begin p 43
###xml 58 60 58 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF</italic>
###xml 65 73 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B-RE-luc</italic>
###xml 73 77 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Carlsen1">[25]</xref>
###xml 316 323 312 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 316 323 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
Specific pathogen-free 8-9-week-old male C3H/HeN mice and NFkappaB-RE-luc[25] (Balb/C) mice were used. Animal care and experimental procedures were performed under approval from the Animal Care Committees of KAIST. To generate the LPS-induced sepsis model, mice were injected intraperitoneally with 15 mg/kg of LPS (E. coli O111:B4; List Biological Laboratories). To generate the CLP-induced sepsis model, mice were anesthetized, and approximately75% of the cecum was ligated and punctured with a 21-gauge needle. The mice received 20 mg/kg of Fc, TOY3, or TOY8 into the peritoneal cavity prior to or after the generation of sepsis.
###end p 43
###begin title 44
Monitoring NF-kappaB activation, measurement of proinflammatory cytokines, and histology
###end title 44
###begin p 45
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF</italic>
###xml 7 15 3 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B-RE-luc</italic>
###xml 15 19 11 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007403-Carlsen1">[25]</xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">Mice</span>
NFkappaB-RE-luc[25] and wild-type mice were given 1.0 and 7.5 mg/kg of LPS 1 hr prior to administration of 20 mg/kg of Fc, TOY3, or TOY8. At 24 hrs after the LPS administration, the luminescence signal was examined by the IVIS imaging system (Xenogen). Plasma was sampled at 6 and 24 hrs, and levels of TNF-alpha, IL-1beta, and IL-6 were measured by ELISA (R&D systems). Mice were sacrificed 24 hours after LPS treatment, and their livers, adrenal glands, lungs, and brains were harvested for histological studies. Harvested organs were fixed using 4% PFA dissolved in PBS at 4degreesC overnight and embedded in paraffin blocks. Sections (4-microm) were stained with H&E and analyzed under a phase-contrast light microscope.
###end p 45
###begin title 46
Statistics
###end title 46
###begin p 47
Values are presented as means +/- S.D. Significant differences between means were determined by analysis of variance followed by the Student-Newman-Keuls test. For analysis of survival curves, a log-rank test was performed.
###end p 47
###begin title 48
Supporting Information
###end title 48
###begin p 49
In vitro binding analysis reveals that TFE, TOY3, or TOY8 could interact not only with MD-2 but also with LPS/MD-2 complex. (A) BSA or MD-2 was coated onto 96-well plates and 40 microg/ml of Fc, TFE, TOY3, or TOY8 was incubated in each well with or without FITC-labeled LPS. An HRP-conjugated anti-Fc antibody was incubated in each well, and then HRP substrate was added. The fluorescence signal of each well is shown. (B) Fluorescence and absorbance were measured. Fluorescence is expressed as radiance (photon/sec/cm2/steradian) on the left y-axis, and absorbance is shown on the right y-axis. Bars represent means +/- S.D. (n = 4). *, P<0.05 versus hMD-2+Fc (5); #, P<0.05 versus hMD-2+FITC-LPS+Fc (9). The x-axis numbering represents the number of each well in (A).
###end p 49
###begin p 50
(1.28 MB TIF)
###end p 50
###begin p 51
Click here for additional data file.
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
The epidemiology of sepsis in the United States from 1979 through 2000.
###end article-title 53
###begin article-title 54
Innate immune sensing and its roots: the story of endotoxin.
###end article-title 54
###begin article-title 55
###xml 68 74 <span type="species:ncbi:9986">rabbit</span>
Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum.
###end article-title 55
###begin article-title 56
Bad news bacteria.
###end article-title 56
###begin article-title 57
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.
###end article-title 57
###begin article-title 58
MD-2 binds to bacterial lipopolysaccharide.
###end article-title 58
###begin article-title 59
The immunopathogenesis of sepsis.
###end article-title 59
###begin article-title 60
Toll-like receptor signaling pathways.
###end article-title 60
###begin article-title 61
TLR signaling.
###end article-title 61
###begin article-title 62
Essential role of MD-2 in LPS responsiveness and TLR4 distribution.
###end article-title 62
###begin article-title 63
Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2.
###end article-title 63
###begin article-title 64
Md-2.
###end article-title 64
###begin article-title 65
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 25 35 <span type="species:ncbi:7227">Drosophila</span>
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.
###end article-title 65
###begin article-title 66
Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
###end article-title 66
###begin article-title 67
The leucine-rich repeat structure.
###end article-title 67
###begin article-title 68
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock.
###end article-title 68
###begin article-title 69
Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2.
###end article-title 69
###begin article-title 70
###xml 22 27 <span type="species:ncbi:9606">human</span>
Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa.
###end article-title 70
###begin article-title 71
Inferences, questions and possibilities in Toll-like receptor signalling.
###end article-title 71
###begin article-title 72
Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling.
###end article-title 72
###begin article-title 73
###xml 28 35 <span type="species:ncbi:71164">hagfish</span>
Structural diversity of the hagfish variable lymphocyte receptors.
###end article-title 73
###begin article-title 74
TLR4 antagonists for endotoxemia and beyond.
###end article-title 74
###begin article-title 75
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 76 91 <span type="species:ncbi:10029">Chinese hamster</span>
Expression and purification of recombinant human angiopoietin-2 produced in Chinese hamster ovary cells.
###end article-title 75
###begin article-title 76
The enigma of sepsis.
###end article-title 76
###begin article-title 77
In vivo imaging of NF-kappa B activity.
###end article-title 77
###begin article-title 78
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4.
###end article-title 78
###begin article-title 79
TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock.
###end article-title 79
###begin article-title 80
###xml 65 71 <span type="species:ncbi:10090">murine</span>
A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.
###end article-title 80
###begin article-title 81
LBP inhibitory peptide reduces endotoxin-induced macrophage activation and mortality.
###end article-title 81
###begin article-title 82
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Effect of CD14 blockade on endotoxin-induced acute lung injury in mice.
###end article-title 82
###begin article-title 83
Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages.
###end article-title 83
###begin p 84
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 84
###begin p 85
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by KOSEF grant funded by the MEST, Korea [R2009-0079390 (GYK)] and was also supported by the KI Biocentury Program funded by KAIST. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 85

